



PATENT Case No. 20620Y

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 11 2001

TECH CENTER 1600/2900

Applicants: C. A. Stump and  
T. M. Williams

Serial No. 09/828,317

Filed: April 6, 2001

For: INHIBITORS OF PRENYL-PROTEIN  
TRANSFERASE

Art Unit: \_\_\_\_\_

Examiner: \_\_\_\_\_

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By [Signature] Date 7/5/01

**INFORMATION DISCLOSURE STATEMENT**

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

By: David A. Muthard

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 35,297

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3903

Date: July 5, 2001



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** C. A. Stump and T.M. Williams

**Serial No.:** 09/828,317

**Case No.:** 20620Y

**Art Unit:** 1614

**Filed:** April 6, 2001

**Examiner:**

**For:** INHIBITORS OF PRENYL-PROTEIN  
TRANSFERASE

Assistant Commissioner for Patents  
Washington, D.C. 20231

**LETTER UNDER 37 C.F.R. §1.98(a)(3)**

Sir:

In compliance with 37 C.F.R. 1.98(a)(3) Applicants provide concise explanations as to the relevance of certain non-English references that are submitted with the Information Disclosure Statement that is submitted herewith:

The PCT Publications WO 01/27118 A2 and WO 01/27119 A2 disclose bicyclic imidazolyl amine derivatives that act as NO synthase inhibitors with potential for treating pain and migraine. Particular note is made of Example (Beispiel) 8, page 17 in WO 01/27119 and the specific compounds listed on pages 7-14 of WO 01/27118.


Respectfully submitted,

By: 

David A. Muthard  
Registration No. 35,297  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3903

Date: July 5, 2001



Sheet	1	of	2
-------	---	----	---

**COMPLETE IF KNOWN**

Application Number	09/828,317
--------------------	------------

<b>Filing Date</b>	April 6, 2001
--------------------	---------------

First Named Inventor	Stump et al.
----------------------	--------------

Group Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number	20620Y
------------------------	--------

TECH CENTER 1600, 29

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 99/09985		Merck & Co., Inc.	03/04/1999
		PCT	WO 99/20609		Merck & Co., Inc.	04/29/1999
		EPC	0 670 314 A1		Kyowa Hakko Kogyo Co., Ltd.	03/30/1995
		PCT	WO 01/27119 A2		Grunenthal GMBH	04/19/2001
		PCT	WO 01/27118 A2		Grunenthal GMBH	04/19/2001

Examiner  
Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

Computer generated form "ID; Form" (IDS Folder), Merck & Co., Inc. 08/15/2000

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

of

2

## COMPLETE IF KNOWN

Application Number 09/828,317  
Filing Date April 6, 2001  
First Named Inventor Stump et al.  
Group Art Unit  
Examiner Name  
Attorney Docket Number 20620Y

RECEIVED  
JUL 11 2001  
TECH CENTER 1600 Z

## OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		A. A. Adjei et al., A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity, Cancer Research, Vol. 60, pp. 1871-1877, April 2000.
		J. Zujewski et al., Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer, J. of Clinical Oncology, Vol. 18, No. 4, pp. 927-941, February 2000.
		N. E. Kohl et al., Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nature Medicine, Vol. 1, No. 8, pp.792-797, August 1995.
		N. E. Kohl et al., Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice, Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 9141-9145, Sept 1994.
		L. Sepp-Lorenzino et al., A Peptidomimetic Inhibitor of farnesyl:Protein Transferase Blocks the anchorage-dependent and -independent Growth of Human Tumor Cell Lines, Cancer Research, Vol. 55, pp. 5302-5309, November 1995.
		S. L. Graham et al., Oncologic, Endocrine & Metabolic Inhibitors of Protein Farnesylation, Exp. Opin. Ther. Patents, Vol 6(12), pp.1295-1304, 1996.
		S. L. Graham, Oncologic, Endocrine & Metabolic Inhibitors of Protein Farnesylation: A New Approach to Cancer Chemotherapy, Exp. Opin. Ther. Patents, Vol. 5(12), pp. 1269-1285, 1995.
		G. L. Bolton et al., Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports in Medicinal Chemistry, Vol. 29, pp. 165-174, 1994.
		B. N. Balasubramanian et al., Recent Developments in Cancer Cytotoxics, Annual Reports in Medicinal Chemistry, Vol. 33, pp. 151-162, 1998.
		T. M. Williams et al., N-Arylpiperazinone Inhibitors of Farnesyltransferase: Discovery and Biological Activity, J. Med. Chem., Vol. 42, pp. 3779-3784, 1999.
		T. M. Williams, Inhibitors of Protein Farnesylation 1998, Exp. Opin. Ther. Patents, Vol. 8(5), pp. 553-569.
		I. M. Bell, Inhibitors of Protein Prenylation 2000, Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1813-1831.
		T. M. Williams, Inhibitors of Protein Prenylation 1999, Exp. Opin. Ther. Patents, Vol. 9(9), pp. 1263-1280.
		F. Aldabbagh et al., Oxidative Radical Cyclisations onto Imidazoles and Pyrroles using Bu <sub>3</sub> SnH, Tetrahedron Letters, Vol. 38, No. 45, pp. 7937-7940, 1997.

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY